Pharmaceutical Contract Manufacturing Market to Reach USD 311.95 Billion by 2030

 The global pharmaceutical contract manufacturing market is witnessing strong momentum. Valued at USD 193.52 billion in 2024, the market reached USD 209.90 billion in 2025 and is projected to grow at a robust CAGR of 8.2% between 2025 and 2030 — ultimately reaching USD 311.95 billion by 2030.

This steady expansion is driven by the increasing demand for GLP-1 manufacturing outsourcing, rising ADC outsourcing for commercialized biologics, and patent expiries of blockbuster drugs leading to a surge in biosimilar production. However, pricing pressure in the US and Europe and the high cost of regulatory compliance (Annex-1, PFAS restrictions) are anticipated to slightly restrain growth.

Download PDF Brochure

Market Overview: Emerging Opportunities and Regional Insights

Asia Pacific: The Fastest-Growing Region

The Asia Pacific region is expected to witness significant growth throughout the forecast period. Factors such as a large patient population, rising demand for innovative therapies, and the emergence of small and mid-sized pharma companies are propelling regional expansion.
Moreover, the growing R&D pipeline, advancements by CDMOs, and the high cost of in-house drug development are pushing companies toward outsourcing solutions. Increasing investments in viral vector, mRNA, and cell & gene therapy manufacturing are also creating lucrative opportunities.

North America: The Market Leader

Globally, North America remains the largest market for pharmaceutical contract manufacturing services, owing to its strong pharmaceutical base, advanced manufacturing infrastructure, and robust R&D investments. The US, in particular, is witnessing growing demand for biologics and generics, sustaining its leadership position.

Key Market Dynamics

1. Driver: GLP-1 Capacity Expansion

The rising demand for GLP-1 drugs such as Ozempic, Wegovy, Rybelsus, Zepbound, and Mounjaro, whose combined revenues touched USD 90 billion in 2024, has created a capacity crunch.
To address this, CDMOs are rapidly expanding peptide manufacturing facilities. For example:

  • Corden Pharma announced a USD 1 billion investment in peptide production and a USD 500 million greenfield facility near Basel, Switzerland.
  • Curia and OneSource expanded vial filling and fill-finish capabilities in 2024–2025.
    The patent expiry of semaglutide (2025–2032) will further drive outsourcing demand and volume growth.

2. Restraint: Complex Regulatory Compliance

Strict global regulations such as Annex 1 (sterile fill-finish), DSCSA (product tracking), and EU PFAS restrictions increase the operational burden on CDMOs. Compliance failures can lead to financial losses and reputational damage, making this a major market restraint.

3. Opportunity: Growth in Emerging Markets

Emerging CDMO hubs like China, India, South Korea, Taiwan, and Singapore are offering cost-effective, skilled manufacturing ecosystems.
Companies such as WuXi Biologics, Samsung Biologics, Asymchem, Jubilant Pharmanova, and Divi’s Laboratories are leading the regional charge. Meanwhile, global players like Thermo Fisher, Lonza, and Boehringer Ingelheim are expanding their regional presence through partnerships and facility upgrades.

4. Challenge: Global Trade Instability and Insourcing

Trade policy changes — such as the US Biosecure Act (2024) and renewed domestic manufacturing initiatives (2025) — have impacted outsourcing from US companies to Asia.
Major pharma firms like Eli Lilly and Pfizer are increasingly investing in US-based manufacturing, which may reduce long-term outsourcing demand. Political uncertainty and trade restrictions continue to pose risks to global CDMO operations.

Market Ecosystem

The pharmaceutical contract manufacturing ecosystem includes:

  • End users: Large, mid-sized, and generic pharmaceutical companies
  • Service providers: CDMOs, CROs, and specialized technology partners
  • Regulatory bodies: Ensuring compliance, quality, and safety standards
  • Collaborative networks: Facilitating R&D partnerships and technology exchange

Together, these stakeholders drive innovation and efficiency across the global drug manufacturing value chain.

Request Sample Pages

Segmental Analysis

By Service: Pharmaceutical Manufacturing Services Lead the Market

In 2024, pharmaceutical manufacturing services dominated the global market, driven by the rising demand for biologics and biosimilars. Increasing consumption of complex therapeutics and technological advancements in manufacturing have further fueled segment growth.
Leading CDMOs are focusing on capacity expansions, facility upgrades, and strategic collaborations to meet evolving production and regulatory demands.

By End User: Big Pharmaceutical Companies to Exhibit Highest Growth

Big pharma companies are expected to record the highest CAGR through 2030, fueled by growing biologics pipelines, rising R&D investments, and strategic partnerships with CDMOs. Their focus on cell and gene therapies and targeted treatments necessitates advanced manufacturing capabilities, making outsourcing an efficient and scalable strategy.

Regional Insights

  • North America: Largest market; strong R&D ecosystem and advanced infrastructure
  • Europe: Second-largest market; growing focus on biosimilar manufacturing
  • Asia Pacific: Fastest-growing region; low-cost production and skilled workforce
  • Latin America, Middle East & Africa: Emerging potential through localization and investment

Recent Developments

  • June 2025: WuXi Biologics announced a new 60,000L microbial manufacturing site in Chengdu, China.
  • July 2025: Thermo Fisher acquired Sanofi’s sterile manufacturing site in Ridgefield, New Jersey.
  • October 2024: Thermo Fisher launched Accelerator Drug Development, an end-to-end drug development suite.
  • March 2024: Lonza acquired Roche’s large-scale biologics manufacturing site in Vacaville, California.

Leading Market Players

  • Thermo Fisher Scientific Inc. (US)
  • Lonza Group (Switzerland)
  • WuXi AppTec & WuXi Biologics (China)
  • AbbVie, Inc. (US)
  • Catalent Inc. (US)
  • Samsung Biologics (South Korea)
  • Evonik Industries AG (Germany)
  • FUJIFILM Holdings Corporation (Japan)
  • Siegfried Holding AG (Switzerland)
  • Boehringer Ingelheim (Germany)
  • Merck KGaA (Germany)
  • Almac Group (UK)
  • Charles River Laboratories (US)
  • Asymchem Inc. (China)
  • Vetter Pharma (Germany)
  • Alcami Corporation (US)

Conclusion

The pharmaceutical contract manufacturing market is entering a transformative phase, driven by biologics expansion, GLP-1 demand, and technological innovation. While regulatory complexity and trade instability pose challenges, regional diversification and strategic collaborations are expected to sustain long-term growth.
As the industry evolves, CDMOs that invest in capacity expansion, digitalization, and global compliance will remain at the forefront of this USD 300+ billion opportunity.

Comments

Post a Comment

Popular posts from this blog

Adhesion Barrier Industry worth $0.9 billion by 2028, with a CAGR of 7.4%

  The report   " Adhesion Barrier Market  by Product (Regenerated Cellulose, Hyaluronic Acid, PEG), Type (Film, Gel, Liquid), Procedure (Abdominal, Cardiovascular, Gynae, Neurology), End User (Hospitals, Clinics & ASC), Region- Global Forecast to 2028" , is valued at an estimated USD 0.7 billion in 2023 and is projected to reach USD 0.9 billion by 2028, at a CAGR of 7.4% during the forecast period. The main drivers of this market's expansion are the rising number of surgeries and sports-related injuries, an increasing elderly population, and a growing understanding by of the adhesion formation and health issues linked to adhesions. On the other hand, during the forecast period, it is projected that surgeons' resistance to using adhesion barriers will impede market expansion. Browse 207 market data Tables and 50 Figures spread through 238 Pages and in-depth TOC on  "Adhesion Barrier Market by Product (Regenerated Cellulose, Hyaluronic Acid, PEG), Type (F...
Read more

Exploring the Versatile Uses of Liquid Biopsies in Modern Medicine

Image
 In recent years, liquid biopsy has emerged as a groundbreaking tool in the field of medicine, offering a less invasive alternative to traditional tissue biopsies. This innovative technique, which involves the analysis of biomarkers in bodily fluids such as blood, urine, or saliva, is revolutionizing the way we diagnose, monitor, and treat various diseases. Let’s delve into the versatile uses of liquid biopsies and how they are transforming healthcare. Download PDF Brochure 1. Cancer Detection and Diagnosis One of the most significant uses of liquid biopsy is in the early detection and diagnosis of cancer. Traditional tissue biopsies can be invasive, painful, and sometimes risky. In contrast, liquid biopsies offer a non-invasive way to detect cancerous cells or DNA fragments (circulating tumor DNA or ctDNA) in the bloodstream. This allows for the identification of cancer at an earlier stage, often before symptoms appear, which can lead to more effective treatment options and i...
Read more

Exploring the Impact of Animal Genetics Testing: Revolutionizing Animal Breeding and Health

Image
 In recent years, animal genetics testing has emerged as a game-changer in the field of veterinary science and animal breeding. By unlocking the genetic makeup of animals, this innovative technology allows for a deeper understanding of their traits, health, and lineage. The implications of these insights are profound, offering significant benefits for breeders, farmers, veterinarians, and pet owners alike. Download PDF Brochure Understanding Animal Genetics Testing Animal genetics testing involves analyzing an animal's DNA to identify specific genetic markers associated with various traits and conditions. These tests can be used to determine parentage, predict the likelihood of certain diseases, and even select for desirable traits in breeding programs. The technology behind these tests has advanced rapidly, making them more accessible and affordable than ever before. Applications in Breeding One of the most significant applications of animal genetics testing is in selecti...
Read more